Author

Heidi Anne Neubauer

University of Veterinary Medicine ViennaORCID 0000-0001-7372-7786Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

Boris TichýiD· 2 shared Lukas KenneriD· 2 shared Michaela SchledereriD· 2 shared Richard MoriggliD· 2 shared Sandra HögleriD· 2 shared Torben RedmeriD· 2 shared Vojtěch BystrýiD· 2 shared Adam Varady· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Boris TichýORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologyHemaSpherePeer-reviewedApr 1, 2026

A STAT5B-driven mouse model of hepatosplenic γδ T-cell lymphoma reveals therapeutic efficacy of JAK inhibition

Myint Myat Khine Aung, Susann Schönefeldt, Sophie Pfalz-Kraupp…·Heidi Anne Neubauer

DOI 10.1002/hem3.70345

mousebulk RNA-seq

𝕏 PostBluesky

Cancer BiologyMolecular CancerPeer-reviewedOct 14, 2025

Thyroid Hormone Receptor Beta Signaling is a Targetable Driver of Prostate Cancer Growth

Aleksandra Fesiuk, Daniel Pölöske, Elvin D. de Araujo…·Lukas Kenner

This study identifies TRβ as a driver of prostate cancer growth and shows that NH-3 inhibits PCa cell proliferation and tumor growth, particularly in castration-resistant models.

DOI 10.1186/s12943-025-02451-2

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyMolecular CancerPeer-reviewedOct 31, 2024

Cell-autonomous GP130 activation suppresses prostate cancer development via STAT3/ARF/p53-driven senescence and confers an immune-active tumor microenvironment

Christina Sternberg, Martin Raigel, Tanja Limberger…·Lukas Kenner

This study shows that activating GP130 in prostate epithelial cells suppresses tumor growth through senescence and immune activation, suggesting a new therapeutic approach.

17 citations

humanbulk RNA-seq

𝕏 PostBluesky